ORIGINAL RESEARCH

Enhanced Heart Failure in Redox-Dead Cys17Ser PKARlα Knock-In Mice

M. M. Towhidul Islam*, PhD; Daniel Tarnowski, MD*; Min Zhang*, MD, PhD; Maximilian Trum*, MD; Simon Lebek, MD; Julian Mustroph, MD; Henriette Daniel, MD; Johanna Moellencamp, MD; Steffen Pabel, MD; Samuel Sossalla, MD; Ali El-Armouche, MD; Viacheslav O. Nikolaev*, PhD; Ajay M. Shah*, MD; Philip Eaton*, PhD; Lars S. Maier*, MD; Can Martin Sag, MD†; Stefan Wagner*, MD†

BACKGROUND: PKARlα (protein kinase A type I-α regulatory subunit) is redox-active independent of its physiologic agonist cAMP. However, it is unknown whether this alternative mechanism of PKARlα activation may be of relevance to cardiac excitation–contraction coupling.

METHODS AND RESULTS: We used a redox-dead transgenic mouse model with homozygous knock-in replacement of redox-sensitive cysteine 17 with serine within the regulatory subunits of PKARlα (KI). Reactive oxygen species were acutely evoked by exposure of isolated cardiac myocytes to AngII (angiotensin II, 1 µmol/L). The long-term relevance of oxidized PKARlα was investigated in KI mice and their wild-type (WT) littermates following transverse aortic constriction (TAC). AngII increased reactive oxygen species in both groups but with RIα dimer formation in WT only. AngII induced translocation of PKARlα to the cell membrane and resulted in protein kinase A–dependent stimulation of ICa (L-type Ca current) in WT with no effect in KI myocytes. Consequently, Ca transients were reduced in KI myocytes as compared with WT cells following acute AngII exposure. Transverse aortic constriction–related reactive oxygen species formation resulted in RIα oxidation in WT but not in KI mice. Within 6 weeks after TAC, KI mice showed an enhanced deterioration of contractile function and impaired survival compared with WT. In accordance, compared with WT, ventricular myocytes from failing KI mice displayed significantly reduced Ca transient amplitudes and lack of ICa stimulation. Conversely, direct pharmacological stimulation of ICa using Bay K8644 rescued Ca transients in AngII-treated KI myocytes and contractile function in failing KI mice in vivo.

CONCLUSIONS: Oxidative activation of PKARlα with subsequent stimulation of ICa preserves cardiac function in the setting of acute and chronic oxidative stress.

Key Words: heart failure ■ pressure overload ■ protein kinase A ■ redox

Heart failure (HF) is a state of impaired systolic and/or diastolic cardiac function (ie, reduced contractility and/or relaxation). At the cellular level, failing myocytes display a typical pattern of severely impaired intracellular Ca handling, pathologically increased reactive oxygen species (ROS), and altered activity of stress kinases such as CaMKII (Ca/calmodulin-dependent protein kinase II) and cAMP (3’,5’-cyclic adenosine monophosphate)-dependent PKA (protein kinase A)1,2. Impaired contractile function in HF is a direct consequence of a reduction in the amplitude of the systolic Ca transient, which results from decreased transsarcolemmal Ca influx (ICa) through the LTCC (L-type Ca channel), and reduced Ca release from the Ca-depleted sarcoplasmic reticulum (SR). Disease-related...
Nonstandard Abbreviations and Acronyms

| Abbreviation | Description |
|--------------|-------------|
| AngII        | angiotensin II |
| CaMKII       | Ca/calmodulin-dependent protein kinase II |
| ECC          | excitation–contraction coupling |
| FRET         | Förster-resonance energy transfer |
| I<sub>Ca</sub> | L-Type Ca current, i.e., inward Ca current through the L-type Ca channel |
| Ki           | knock-in |
| LTCC         | L-type Ca channel |
| Nox2         | nicotinamide adenine dinucleotide phosphate oxidase 2 |
| Nox4         | nicotinamide adenine dinucleotide phosphate oxidase 4 |
| PDGF         | platelet-derived growth factor |
| PKA [C]      | protein kinase A catalytic subunit |
| PKA          | protein kinase A |
| PKARII       | protein kinase A type II regulatory subunit |
| PKARI<sub>α</sub> | protein kinase A type I-α regulatory subunit |
| PLB          | phospholamban |
| ROS          | reactive oxygen species |
| RyR2         | ryanodine receptor type 2 |
| SERCA2a      | SR Ca ATPase 2a |
| SR           | sarcoplasmic reticulum |
| TAC          | transverse aortic constriction |
| WT           | wild-type |

What Are the Clinical Implications?

- Our study demonstrates an important compensatory function for redox-activated PKARI<sub>α</sub> in the course of pressure overload–induced heart failure, which should be carefully considered when using antioxidant treatment for heart failure.

What Is New?

- The role of redox-activated PKARI<sub>α</sub> in cardiac excitation–contraction coupling is largely unknown.
- Oxidative activation of PKARI<sub>α</sub> with subsequent stimulation of I<sub>Ca</sub> preserves cardiac function in the setting of acute and chronic oxidative stress.
- Conversely, enhanced heart failure is observed in redox-dead Cys<sup>17</sup>Ser PKARI<sub>α</sub> knock-in mice upon pressure overload as induced by transverse aortic constriction.

ROS may contribute to impaired Ca handling in HF, because ROS were shown to inhibit I<sub>Ca</sub> and to decrease SR Ca content as a consequence of inhibited SR Ca reuptake and enhanced diastolic SR Ca loss. Furthermore, ROS may also indirectly aggravate SR Ca loss by activation of stress kinases such as CaMKII, which results in a CaMKII-dependent diastolic SR Ca leak. The pathologic relevance of redox-dependent CaMKII activation has been extensively investigated in the past few years and was identified to be involved in several cardiac diseases including myocardial injury and HF.

PKA is another important protein kinase, which shares many important targets with CaMKII in excitation–contraction coupling (ECC) (such as LTCC and PLB [phospholamban]). PKA is the major downstream effector of enhanced β-adrenergic stimulation. However, HF is characterized by a blunted response to β-adrenergic signaling, and there is evidence for an impaired β-adrenergic reserve for I<sub>Ca</sub> stimulation in HF. Thus, reduced PKA-dependent stimulation of Ca handling proteins such as the LTCC or PLB (that regulates SR Ca reuptake) may contribute to contractile dysfunction in HF. PKA consists of 4 different types of regulatory (i.e., RI<sub>α</sub>, RI<sub>β</sub>, RII<sub>α</sub>, and RII<sub>β</sub>) and 2 different types of catalytic subunits (PKA [C]). Regulatory subunit RIIα has been shown to be important for regulation of PKA activity in the brain, brown and white adipose tissue, skeletal muscle, and sperm. Its essential requirement was further proven by a RI<sub>α</sub> knock-out in mice, which results in early embryonic lethality because of aberrant cardiac morphogenesis. RI<sub>α</sub> is unique among the regulatory subunits because it contains redox-sensitive cysteine residues. Brennan et al found that oxidation of RI<sub>α</sub> can result in cAMP-independent PKA activation, which results in a positive inotropic response in isolated cardiac myocytes. This alternative oxidant-dependent activation of PKARI<sub>α</sub> has been shown to be important for angiogenesis during tumor formation and ischemia, as well as for PDGF (platelet-derived growth factor)-dependent signaling. Recently, oxidative activation of RI<sub>α</sub> was shown to protect against myocardial ischemia–reperfusion injury in the acute setting of global ischemia ex vivo, presumably through inhibition of lysosomal-triggered Ca release. This suggests that oxidative RI<sub>α</sub> activation may be an important acute regulator of cardiac inotropy. However, distinct targets of oxidized PKARI<sub>α</sub> in ECC that may underlie its inotropic potential as well as the long-term consequences of oxidative RI<sub>α</sub> activation in vivo (i.e., in cardiac pathology) have not been investigated. We have recently reported that oxidized PKARI<sub>α</sub> acutely regulates potassium currents in cardiac myocytes upon H<sub>2</sub>O<sub>2</sub>, thereby contributing to early afterdepolarizations in vitro.
study did not investigate the role of oxidized PKAR\(\alpha\) for cardiac contractility (neither for the acute setting in vitro nor for the long-term setting in vivo), nor did it investigate the distinct molecular targets of oxidized PKAR\(\alpha\) in ECC that may underlie its inotropic relevance. Interestingly, AngII (angiotensin II)-dependent regulation of \(I_{\text{Ca}}\) was shown to require Nox2 (nicotinamide adenine dinucleotide phosphate oxidase 2)-related ROS and PKA,\(^5\) which suggests that oxidized PKAR\(\alpha\) could be of particular relevance for \(I_{\text{Ca}}\) gating and hence for cardiac inotropy. We accordingly hypothesized that oxidative activation of PKAR\(\alpha\) might be an important regulator of excitation–contraction coupling upon increased oxidative stress. We made use of a redox-dead transgenic mouse model with homozygous knock-in replacement of redox-sensitive cysteine 17 with serine (within the regulatory subunits of PKAR\(\alpha\) (KI)).

As a model of acute oxidative stress, isolated cardiac myocytes from KI hearts were exposed to AngII. In addition, we tested the relevance of oxidized PKAR\(\alpha\) under conditions of long-term increased ROS formation and impaired \(\beta\)-adrenergic signaling (ie, upon pressure overload–induced HF by transverse aortic constriction (TAC)).

Our data show that oxidative activation of PKAR\(\alpha\) is required to maintain \(I_{\text{Ca}}\) both upon acute exposure to AngII and during pressure overload–induced HF, which identifies oxidized PKAR\(\alpha\) as an important contributor of maintained Ca handling upon oxidative stress. Conversely, KI mice with absent stimulation of \(I_{\text{Ca}}\) (and reduced Ca transients) developed aggravated heart failure and decreased survival following TAC that can be acutely rescued by cAMP-independent stimulation of \(I_{\text{Ca}}\) using Bay K8644.

**METHODS**

All animal procedures were performed in accordance with the guide for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee. Data are available upon reasonable request to the authors. An extended description of materials and methods can be found in Data S1.

**In Vivo Procedures**

**Generation of Cys17Ser PKAR\(\alpha\) Mice**

Mice that constitutively express PKAR\(\alpha\) Cys17Ser (KI) were generated as previously described.\(^{16}\) The point mutation Cys17Ser was introduced into exon 1 of the \(Ptkar1a\) gene by site-directed mutagenesis. These mice behave normally under physiologic conditions.

**Transverse Aortic Constriction**

Male mice at the age of 11 to 13 weeks (weight, 20–25 g) were subjected to transverse aortic constriction as previously described.\(^{20}\) Briefly, a small incision was made into the skin above the upper thoracic inlet (~1 cm), and a 6-0 nonabsorbable suture was used to form a knot around the transverse aorta between the right and left carotid artery. The knot was tightened against a 27-gauge cannula. For control, a sham procedure was conducted applying a similar surgical procedure but without constriction of the aorta. Sham-operated mice had normal survival and did not develop HF. Echocardiographic data of sham-operated mice are given in Table 1.

**Echocardiography**

Echocardiography was performed on anesthetized mice (isoflurane 1.5%, spontaneous respiration) at different time points (ie, at baseline, at 1 week after TAC, and at 6 weeks after TAC respectively) by experienced ultrasonographers who were unaware of the mice’s treatment details. In some experiments, \(I_{\text{Ca}}\) was acutely stimulated by IP injection of 100 mg/kg Bay K8644 in anesthetized wild-type (WT) and KI mice undergoing echocardiography at 1 week after TAC. The maximum of the acute inotropic response (ie, a Bay K8644–dependent change in left ventricular ejection fraction [LVEF]) was reached at ~6 minutes after Bay K8644 injection and was therefore taken for analysis.

**Electrophysiological Studies**

Mice were anesthetized with isoflurane and kept on a warm pad as mentioned above. A baseline surface ECG (lead II) was acquired using a multichannel data-acquisition system (Powerlab 16/30; AD Instruments, Colorado Springs, CO). Data were stored using Labchart Pro software version 7 (AD Instruments). QT intervals were heart rate corrected (QTc) using Mitchell’s formula.\(^{21}\) Afterward, a standard clinical protocol was used to determine electrophysiological parameters. In brief, right atrial or ventricular pacing was performed using 2-millisecond current pulses delivered by an external stimulator (STG-3008; Multi Channel Systems). Inducibility of ventricular arrhythmias was tested by decremental burst pacing. Burst pacing started at a 40-millisecond cycle length, decreasing by 2 milliseconds every 2 seconds to a cycle length of 20 milliseconds. Burst pacing was repeated 1 minute after the previous burst concluded or the termination of arrhythmias. Burst pacing was performed for a total of 5 times for ventricular stimulation, respectively. Ventricular tachycardia was defined as rapid ventricular potentials that occurred...
Table 1. Echocardiographic Parameters

|                | WT basal | KI basal | WT sham, 1 wk | WT TAC, 1 wk | KI sham, 1 wk | KI TAC, 1 wk | WT sham, 6 wk | WT TAC, 6 wk | KI sham, 6 wk | KI TAC, 6 wk | P value for interaction |
|----------------|----------|----------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|------------------------|
| No. of mice    | 92       | 85       | 9            | 38           | 8            | 38           | 4            | 18           | 4            | 14          |                        |
| HR, bpm        | 431±3    | 430±8    | 458±13       | 429±7        | 441±11       | 441±6        | 456±20       | 460±12       | 450±13       | 462±10       | 0.7776                 |
| FS, %          | 24.5±0.5 | 24.5±0.5 | 23.9±2.2     | 18.1±0.9     | 23.2±1.8     | 14.3±0.9     | 22.1±1.8     | 13.3±1.2     | 24.7±2.6     | 7.2±1.0      | 0.0014*                |
| EF, %          | 48.3±0.7 | 48.8±0.7 | 47.6±4.0     | 38.0±1.5     | 46.4±3.2     | 31.4±1.6     | 47.2±4.0     | 29.7±2.2     | 50.1±3.8     | 20.6±1.6     | 0.0004*                |
| SV, µL         | 39.9±0.6 | 39.2±0.7 | 34.9±2.9     | 30.7±1.2     | 37.5±2.2     | 26.2±1.4     | 42.2±2.5     | 31.6±1.7     | 38.0±2.7     | 26.8±1.7     | 0.0487*                |
| CO, mL/min     | 17.1±0.3 | 17.0±0.4 | 15.9±1.2     | 13.1±0.6     | 16.5±1.0     | 11.6±0.7     | 19.3±1.7     | 14.5±0.9     | 17.1±1.4     | 13.0±0.8     | 0.1922                 |
| LVEDD, mm      | 4.25±0.03| 4.19±0.04| 4.09±0.06    | 4.19±0.06    | 4.23±0.07    | 4.23±0.06    | 4.40±0.11    | 4.76±0.11    | 4.19±0.10    | 4.93±0.11    | 0.4503                 |
| LVESD, mm      | 3.32±0.04| 3.32±0.04| 3.26±0.11    | 3.46±0.08    | 3.37±0.12    | 3.72±0.08    | 3.44±0.17    | 4.16±0.14    | 3.19±0.15    | 4.61±0.13    | 0.0183*                |
| LVEDV, µL      | 82.9±1.5 | 81.0±1.4 | 74.1±2.4     | 83.1±3.7     | 81.6±3.2     | 86.6±4.8     | 87.5±5.4     | 112.2±6.6    | 76.2±4.1     | 134.3±8.2    | 0.0036*                |
| LVESV, µL      | 43.2±1.3 | 41.7±1.1 | 39.1±3.8     | 52.4±3.2     | 44.1±4.0     | 60.4±3.9     | 43.4±4.7     | 80.6±6.7     | 38.2±4.1     | 107.5±7.9    | 0.0002*                |
| AWThd, µm      | 0.79±0.02| 0.80±0.02| 0.79±0.03    | 1.02±0.04    | 0.80±0.04    | 1.00±0.03    | 0.73±0.03    | 0.92±0.03    | 0.77±0.08    | 0.93±0.03    | 0.8939                 |
| PWThd, µm      | 0.70±0.01| 0.68±0.01| 0.74±0.05    | 0.90±0.04    | 0.73±0.05    | 0.91±0.04    | 0.65±0.02    | 0.82±0.04    | 0.69±0.10    | 0.78±0.04    | 0.7879                 |

AWThd indicates anterior wall thickness, diastolic; CO, cardiac output; EF, ejection fraction; FS, fractional shortening; HR, heart rate; KI, knock-in; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; PWThd, posterior wall thickness, diastolic; SV, stroke volume; TAC, transverse aortic constriction; and WT, wild-type.

* P<0.05 in mixed-effects model type III test WT vs. KI (without sham groups).

dependent from atrial potentials and displayed altered QRS morphology. If ventricular tachycardia was sustained for >1 second, it was considered as relevant.

Blood Pressure Measurements

AngII (1.0 mg/kg·1 per d−1) was administered for 14 days via subcutaneous osmotic minipumps (model 1002; Alzet, Cupertino, CA) implanted under 2% isoflurane as described previously.22 Mean blood pressure was assessed using the CODA mouse rat tail-cuff system (Kent Scientific). We allowed mice to acclimatize to a clear acrylic tube with a nose cone holder (Kent Scientific) for at least half an hour before blood pressure recordings were started. Mean blood pressure was assessed at baseline and following 14 days of AngII treatment. A minimum of 20 blood pressure recordings were averaged for each mouse.

In Vitro Experiments

Isolation of Mouse Ventricular Myocytes

Ventricular cardiomyocytes were isolated according to established enzymatic procedure as previously described.23 Only adult male mice aged 10 to 20 weeks were used.

Measurement of Intracellular Ca Transients, Ca Spark Frequency, and Cytosolic ROS

Intracellular Ca transients were measured as described previously using standard Tyrode’s solution.5 Briefly, myocytes on laminin-coated recording chambers were loaded with 10 µmol/L Fura-2-AM, in the presence of 0.02% (w/v) pluronic acid (Molecular Probes, Eugene, OR) for 20 minutes at room temperature in the dark. All fluorescence emission was recorded using IonWizard software (IonOptix, Boston, MA). For some experiments, caffeine (10 mmol/L) was applied to induce rapid SR Ca release. Ca spark frequency was measured.

Figure 1. Acute exposure to Angiotensin II stimulates reactive oxygen species (ROS) and PKARIA regulatory subunit oxidation.

Original traces (A) and mean data (B) of isolated ventricular myocytes from wild-type (WT) and knock-in (KI) mice loaded with the ROS sensor CellROX that were acutely exposed to AngII (angiotensin II). For improved visualization, gray scale values were converted to color using the depicted calibration bar. F/F0 indicates fluorescence intensity normalized to baseline fluorescence. AngII induced cytosolic ROS to a similar extent in WT and KI myocytes. Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs baseline using mixed-effects analysis with Holm-Sidak post-test. C, An original Western blot of PKARIA dimer formation (ie, oxidation) in isolated WT and KI hearts perfused with AngII (1 µmol/L, 10 minutes). Upon nonreducing conditions, monomeric PKARIA subunits form a band at around 50 kDa, whereas oxidized PKARIA dimers have twice the molecular weight (at around 100 KDa). Compared with vehicle (AngII−), AngII increased PKARIA oxidation in WT only. Original traces (D) and mean values (E) for immunocytochemical analysis of PKARIA (protein kinase A type I regulatory subunit) localization in isolated mouse ventricular myocytes. Scale bar in (D)=10 µm. Insets show magnification of subcellular localization at nucleus, transverse tubules (TT), and intercalated discs (ICD). For improved visualization, grayscale values were converted to color using the depicted calibration bar. Interestingly, exposure to AngII resulted in significantly enhanced PKARIA translocation to these specific regions of interest. At least 3 independent mice were used per group. Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs vehicle using 1-way ANOVA with Holm-Sidak post-test.
assessed in isolated ventricular myocytes loaded with 10 µmol/L Fluo-4 AM (Molecular Probes) for 12 minutes at room temperature using an inverted laser scanning confocal microscope (Zeiss Pascal 5; Carl Zeiss) as described previously.5 Cytosolic ROS production was measured in ventricular myocytes loaded with CellROX (Molecular Probes) at 5 µmol/L for 20 minutes at room temperature in the dark using an inverted
laser scanning confocal microscope (Zeiss Pascal 5). CellROX was excited at 545 nm, and emission was collected at 565 nm. Once every minute, CellROX emission was measured and normalized to the basal fluorescence for further comparison. In some experiments, myocytes were exposed to AngII (1 µmol/L) for 15 minutes. PKA was inhibited using 5 µmol/L of H89. In another set of experiments, AngII pretreated cells were acutely exposed to 1 µmol/L of BayK8644.

**Patch-Clamp Experiments**

Ruptured-patch whole-cell voltage clamp was used to measure $I_{Ca}$ (voltage clamp configuration). In all experiments, myocytes were mounted on the stage of a microscope (Nikon Eclipse TE2000-U). For $I_{Ca}$ measurements, microelectrodes (2–3 MΩ) were filled (in millimoles per liter) with 86 CsCl, 40 Cs-glutamate, 0.92 MgCl2, 5 Mg-ATP, 0.3 Li-GTP, 10 HEPES, 5 EGTA, and 1.8 CaCl2 (free [Ca$^{2+}$i] 100 nmol/L) (pH 7.2, CsOH). The bath solution contained (in millimoles per liter) 140 NaCl, 4 CsCl, 1 MgCl2, 10 glucose, 10 HEPES, 1 CaCl2 (pH 7.4, CsOH). For $I_{Ca}$, access resistance was <8 MΩ. Signals were filtered with 2.9 and 10 kHz Bessel filters and recorded with an EPC10 amplifier (HEKA Elektronik). Recordings were started 2 to 3 minutes after rupture. All experiments were conducted at room temperature.

**Measurement of cAMP Levels Using Förster Resonance Energy Transfer (FRET) with Fluorescence Lifetime Imaging Microscopy (FLIM)**

Quantification of intracellular cAMP generation was performed in isolated adult ventricular Epac1-camps-transgenic mouse cardiomyocytes from sham versus TAC-operated mice using Förster-resonance energy transfer (FRET). As previously described, intracellular cAMP concentration can be traced back to a change in Epac1-camps FRET signal. However, the spectral separation of 2 fluorescence emissions cannot be performed with absolute precision when using the conventional ratiometric measurement of FRET on an inverted fluorescence microscope. Therefore, we applied a more accurate approach to measure FRET signal by fluorescence lifetime imaging microscopy (FLIM). After isolation, myocytes were placed on a laminin-coated recording chamber that was mounted on a specialized confocal microscope (DCS-120; Becker & Hickl). Every 60 seconds an image of the chosen myocyte was recorded for a total of 14 minutes. Starting minute 3, forskolin (50 µmol/L) was applied to induce maximum stimulation of cAMP generation. Imaging data were collected and analyzed using SPCIImage version 6.4 (Becker & Hickl).

**Assessment of Cardiac cAMP Concentration and PKA Activity**

To study the effect of TAC on cAMP concentration and PKA activity in cardiac tissue samples, a cAMP ELISA kit (Enzo Life Sciences, Lausen, Switzerland) and a PKA kinase activity assay (ab139435; Abcam, Berlin, Germany) were performed according to the manufacturer’s protocol.

**Histology**

Cardiac samples were immediately fixed in formalin and embedded in paraffin according to standard procedures. Then, 4-µm sections were stained with antibodies directed against wheat germ agglutinin (at 1:300, Alexa Fluor 594; Life Technologies, Eugene, OR) and biotinylated Griffonia (Bandeiraea) Simplicifolia Lectin I (isolectin B4 at 1:200; Vector Laboratories, Burlingame, CA). To quantify cardiac fibrosis, the trichrome stain (Masson) kit was used (Sigma-Aldrich, St. Louis, MO). All images were acquired on a Zeiss Axiostar plus microscope using the Axio Vision 4.9.1. software (Carl Zeiss Microscopy, Jena, Germany). Morphometric analysis was performed using Histo Quest software (TissueOnistics, Vienna, Austria). All data were analyzed by one observer blinded to mouse genotypes.

**Western Blot Analysis**

Both isolated cardiomyocytes and whole mouse heart samples were used for Western blot analysis. Immunoblots detecting the PKAα dimer to monomer ratio were performed under nonreducing conditions. As recently described by Simon et al., we also observed a nonspecific band above the PKAα monomer band that was not used for analysis.

**Statistical Analysis**

All data are expressed as mean±SEM. Normality of data was tested by hierarchical application of the D’Agostino-Pearson, Shapiro-Wilk, or Kolmogorov-Smirnov test, respectively, depending on the number of experiments. For some experiments, data were transformed (log, reciprocal) to demask a normality distribution before normality and statistical testing. If data were not normally distributed or the sample size was too small for normality testing, nonparametric tests were used. For longitudinal data, 2-way repeated-measures ANOVA or mixed-effects analysis was performed; where appropriate, a 1-way ANOVA or Kruskal-Wallis test with multiple comparison tests was used. For categorical data, Fisher’s exact test was used. Otherwise, Student’s unpaired t test was applied. Two-sided $P<0.05$ was considered significant. The method of analysis for each data set is given in the figure legends. Statistics were performed using GraphPad Prism 9 (GraphPad Software, San Diego, CA).
Islam et al. Oxidized Protein Kinase A Type I-α Regulatory Subunit Protects Against Heart Failure

Figure 2. AngII acutely regulates L-type Ca current (I_{Ca}) gating by oxidized PKARI_α (protein kinase A type I-α regulatory subunit).

Mean data for peak I_{Ca} voltage relationship (A) and peak I_{Ca} at 0 mV (B) measured by whole-cell patch-clamp technique in isolated mouse ventricular myocytes (protocol depicted on the right in A). Acute exposure to AngII (angiotensin II; 1 μmol/L, 10 minutes) significantly enhances peak I_{Ca}, which could be blocked by inhibition of protein kinase A (PKA) using the PKA inhibitor H89. This AngII-PKA–dependent enhancement of I_{Ca} was completely absent in knock-in (KI) myocytes. Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs wild-type (WT). †Indicates significance vs WT+AngII (2-way repeated-measures ANOVA, mixed-effects model with Tukey post-test).

C and D, Original scans (C) and mean densitometric values (D) for Western blot analysis of L-type Ca channel, alpha 1C subunit (Ca V1.2) expression and serine 1928 phosphorylation (p-LTCC [L-type Ca channel]) in isolated hearts perfused with AngII (1 μmol/L, 10 minutes). Exposure to AngII significantly enhanced LTCC phosphorylation in WT but not KI mice. Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs WT+AngII using 1-way ANOVA with Holm-Sidak post-test.
Acute Exposure to AngII Results in ROS Formation, PKA RIα\(\alpha\) Dimerization, Translocation, and PKA-Dependent Stimulation of \(I_{\text{Ca}}\)

We have previously reported that AngII-mediated ROS regulate LTCC through activated PKA.\(^5\) Here, we acutely exposed isolated cardiomyocytes from KI and WT hearts to AngII to test whether PKA-dependent regulation of \(I_{\text{Ca}}\) upon increased ROS requires oxidized PKARI\(\alpha\).

As shown in Figure 1A and 1B, AngII (1 \(\mu\)mol/L) robustly increased intracellular ROS formation within a time frame of 14 minutes in both WT and KI myocytes without differences between groups. This demonstrates that AngII exposure can be used as an acute model of oxidative stress in isolated cardiac myocytes, and that KI replacement of Cys17 to Ser within the regulatory subunit of PKARI\(\alpha\) does not affect ROS formation upon AngII. In contrast, AngII-dependent ROS formation was associated with PKARI\(\alpha\) dimer formation in WT myocytes only (Figure 1C).

We next investigated PKARI\(\alpha\) localization and subsequent functional alterations in excitation–contraction coupling including \(I_{\text{Ca}}\) gating upon acute AngII exposure. AngII treatment resulted in PKARI\(\alpha\) translocation to subcellular compartments, which are of great relevance for excitation–contraction coupling, including the transverse tubules, intercalated discs, and the nucleus (Figure 1D and 1E). Functionally, AngII-mediated PKARI\(\alpha\) activation significantly increased peak \(I_{\text{Ca}}\) in WT cells, whereas it had no effect on peak \(I_{\text{Ca}}\) in KI cells (Figure 2A and 2B). This stimulatory effect of AngII on \(I_{\text{Ca}}\) was PKA dependent, because the PKA inhibitor H89 (5 \(\mu\)mol/L) completely prevented the increase in peak \(I_{\text{Ca}}\) in the presence of AngII in WT cells. As a potential mechanism of oxidized PKARI\(\alpha\), serine 1928 phosphorylation at LTCC was found to be increased in WT but not in KI myocytes (Figure 2C and 2D).

The functional relevance of PKARI\(\alpha\)-dependent \(I_{\text{Ca}}\) regulation for ECC, respectively, for the systolic Ca transient was further corroborated by the fact that AngII-treated KI myocytes (that lack AngII-dependent stimulation of peak \(I_{\text{Ca}}\)) revealed dramatically decreased Ca transient amplitudes upon AngII treatment at all stimulation frequencies from 0.5 to 3 Hz (Figure 3A and 3B). In contrast, Ca transient decay kinetics that can be taken as an approximate for SR Ca reuptake were found to be unaffected (Figure 3C). AngII exposure further resulted in a similar increase in diastolic Ca leak from the SR (Figure 3D and 3E), and a similarly decreased SR Ca content in KI and WT myocytes (Figure 3F). Notably, PKA inhibition using H89 did not prevent the AngII-mediated increase in SR Ca leak, suggesting a PKA-independent mechanism of AngII-mediated SR Ca leak.

These observations collectively indicate that oxidized PKARI\(\alpha\) is critical for the maintenance of the systolic Ca transient through stimulation of \(I_{\text{Ca}}\) in the context of acute oxidative stress.

Decreased Survival and Enhanced Heart Failure in KI Mice Following TAC

We next aimed to investigate the pathophysiologic relevance of PKARI\(\alpha\)-dependent \(I_{\text{Ca}}\) regulation in the context of long-term cardiac pathology in vivo by performing TAC surgery leading to HF, which is a well-established model of chronic oxidative stress. As recently reported,\(^16,27\) WT and KI mice did not show structural or functional cardiac abnormalities at baseline as revealed by in vivo echocardiography.
Islam et al. Oxidized Protein Kinase A Type I-α Regulatory Subunit Protects Against Heart Failure

(Table 1). However, compared with WT, KI mice had decreased survival following TAC (Kaplan-Meier analysis in Figure 4A). This was associated with aggravated left ventricular (LV) dysfunction already manifesting as early as 1 week after TAC when LVEF was reduced by ~6% (Figure 4B and 4C and Table 1). Interestingly, features of structural LV remodeling like LV hypertrophy (Figure 4D, Figure S1A and S1B), fibrosis (Figure S1C and S1D), or reduced capillary density (Figure S1E and S1F) were not different at 1 week after TAC. This finding suggests that a pathomechanism affecting the contractile function of cardiomyocytes may be present in KI mice in the first days after TAC. In contrast, at 6 weeks after TAC, cellular hypertrophy was significantly more pronounced in KI hearts, and fibrosis slightly increased in trend ($P=0.075$, see Figure S1C and S1D). Consistent with aggravated HF development in KI mice, LVEF deteriorated even more in KI mice (by ~9% as compared with WT) (Figure 4C), and LV dilatation was more evident late after TAC (Figure 4E).
Likewise, wet weight of excised hearts, which integrates LV dilatation (ie, volume) and LV mass, was significantly more increased in KI mice 6 weeks after TAC. Heart weight normalized to body weight was 16.63±1.01 versus 13.57±1.05 mg/g (KI versus WT, P<0.05) indicating functionally and structurally enhanced HF in KI late.
after TAC. In contrast, long-term treatment with pres- sor doses of AngII (at 1 mg/kg·d−1)22 resulted in a similar hypertensive response in WT and KI mice at comparable heart rates (Figure S2), which suggests that oxidized PKARlα may not be of major relevance to blood pressure regulation in the context of chronic oxidative stress.

**Impaired Systolic Ca Transients and Decreased I_{Ca} in KI Myocytes Following TAC**

To test if impaired intracellular Ca handling might contribute to contractile dysfunction and aggravated HF development in KI mice following TAC, Ca handling was assessed in failing myocytes from both genotypes. Consistent with the reduced LVEF that we observed as early as 1 week after TAC in KI mice, we found significantly decreased Ca transient amplitudes (by ~18%) in KI myocytes compared with WT cells at 1 week after TAC (Figure 5A and 5B). In line with this, Ca transient decay was also impaired in KI at 1 week after TAC (Figure 5C). However, the reduction in Ca transient amplitude was not accompanied by reduced SR Ca content or enhanced diastolic SR Ca leak (Figure 5D through 5F), suggesting that the SR Ca leak may not be directly regulated by oxidative-activated PKARlα and does not underlie reduced Ca transients in the early stage after TAC. Moreover, this observation points to reduced Ca entry through the LTCC as the underlying cause of decreased Ca transients in KI myocytes following TAC. Original traces and quantitative data for the current–voltage relationship revealed that TAC led to a failure of peak I_{Ca} stimulation in KI myocytes at 1 week after TAC, a phenomenon that was present in WT myocytes only (Figure 6). Consistent with the progressive deterioration of LVEF at 6 weeks after TAC, peak I_{Ca} was significantly decreased in KI as compared with baseline, whereas peak I_{Ca} of WT cells was found to be normalized to baseline conditions only (Figure 6A through 6C). Importantly, peak I_{Ca} was persistently reduced in KI myocytes as compared with WT cells following TAC (P<0.05 for interaction using 2-way ANOVA). These functional observations suggest that a reduction in transsarcolemmal Ca influx via the LTCC may causally underlie decreased Ca transients in KI myocytes in vitro and presumably decreased cardiac function in vivo.

**PKA Activation and Signaling During TAC-Induced HF Development in KI Hearts**

The enhanced HF development in KI mice after TAC suggests that oxidative activation of PKARlα may be required for the heart to adapt to pressure overload. We therefore aimed to investigate potential upstream signals and downstream targets of oxidized PKARlα to gain further insights into the presumably adaptive PKARlα signaling following TAC. Consistent with previously reported oxidative stress after TAC,27 isolated ventricular myocytes exhibited an enhanced CellROX fluorescence signal as a measure of intracellular ROS production (Figure 7A and 7B). Importantly, there was no difference in ROS production between WT and KI mice after TAC, which implies that the lack of PKARlα oxidation in KI mice is not because of different levels of ROS production following TAC. On the protein level, PKARlα dimerization was completely absent in KI hearts both at baseline and following TAC, with a transient increase in WT at 1 week after TAC (P<0.05 for interaction using 2-way ANOVA (Figure 7C and 7D and Tables 2 through 4). However, expression and PKA-dependent phosphorylation of important SR Ca handling proteins such as the RyR2a (ryanodine receptor 2) (at serine 2809) and PLB (at serine 16) were largely comparable between groups (Figure 7C and Tables 2 through 4), which was in line with our observation of largely unaffected SR Ca handling. We found robust CAMP generation in our TAC model as indicated by the representative FLIM FRET recordings in Figure S3A through S3C, yet intracellular cAMP levels as well as global PKA activity were not different between groups following TAC (Figure 7E and 7F). This again points to the fact that oxidized PKARlα may rather act in distinct intracellular compartments such as within the proximity of the LTCC. We therefore assessed the phosphorylation site serine 1928 at the LTCC at baseline and following TAC (see Figure S4A and S4B) and observed increased serine 1928 phosphorylation following TAC in WT hearts only. As with acute AngII exposure, this finding suggests that oxidized PKARlα may selectively act in close proximity to LTCC, possibly through direct target phosphorylation.

Because Nox4 (nicotinamide adenine dinucleotide phosphate oxidase 4) has been shown to act as
and because Nox4-dependent ROS formation was shown to be involved in PKARlα oxidation, we tested whether Nox4 may be required for PKARlα oxidation in the context of pressure overload as induced by abdominal aortic banding for 6 weeks. As shown in Figure S4C and S4D, the PKARlα dimer-to-monomer ratio was decreased in Nox4 knock-out hearts, which
Figure 5. Lack of oxidized PKARIα (protein kinase A type I-α regulatory subunit) impairs Ca handling as early as 1 week after transverse aortic constriction (TAC).

Stimulation of $I_{\text{Ca}}$ Using Bay K8644 Rescues Ca Transients in AngII-Treated KI Myocytes and LV Function in Failing KI Mice Following TAC

We further aimed to investigate the underlying cause for the observed reduction in survival of KI mice following TAC, which in principle may be a consequence of increased arrhythmogenicity and/or decreased LV contractility (ie, pump failure). As shown in Figure S5A and S5B, HF-related electric remodeling was evident in both groups following TAC in terms of significantly prolonged corrected QT intervals (see also Table S1). Interestingly, ventricular arrhythmias (ie, ventricular tachycardia) could be induced to a similarly increased extent in WT and KI hearts following TAC (Figure SSC and SSD), which speaks against an increased arrhythmogenicity in KI mice as the prime cause of decreased survival following TAC. We therefore tested in a next step whether stimulation of the presumably causative reduction in $I_{\text{Ca}}$ in KI (using Bay K8644 in vivo) would rescue reduced contractility in KI. Bay K8644 significantly increased Ca transient amplitudes in AngII-treated WT and KI myocytes, thereby normalizing the difference between WT and KI cells that was present in the absence of $I_{\text{Ca}}$ stimulation using Bay K8644 (Figure 8A and 8B). Similarly, Bay K8644 led to a significantly increased inotropic response in TAC-operated KI mice (relative increase in ejection fraction by 56%±12%, n=10) as compared with WT mice (by 12%±16%, n=8) at 6 minutes after IP injection in vivo (see Figure 8C and 8D). Importantly, this occurred in the face of unaffected heart rates upon Bay K8644 in both groups (heart rate was 452±16 bpm in WT mice and 460±10 bpm in KI mice following Bay K8644, P=not significant), which in summary underscores the pathologic relevance of reduced $I_{\text{Ca}}$ for impaired cardiac contractility in KI mice in HF.  

DISCUSSION

Our study demonstrates that myocardial PKARIα becomes oxidized upon acute and chronic oxidative stress, induced by acute AngII treatment and in the context of long-term pressure overload, respectively. Myocytes from KI hearts that lack oxidative activation of PKARIα fail to increase $I_{\text{Ca}}$ upon acute stimulation with AngII, whereas KI mice develop enhanced LV dysfunction and have decreased survival upon long-term pressure overload in the face of persistently reduced $I_{\text{Ca}}$. Conversely, pharmacological stimulation of $I_{\text{Ca}}$ using Bay K8644 is capable of restoring Ca transients in AngII-treated KI myocytes and LV function in failing KI mice.

Our study indicates that oxidized PKARIα may act as an adaptive signal in the heart through stimulation of $I_{\text{Ca}}$ both in the context of acute and chronic myocardial oxidative stress. This should be carefully considered when using antioxidant treatment for HF.

ROS Are Signaling Molecules That Activate PKARIα in Specific Compartments of the Cardiomyocyte

HF is characterized by increased myocardial ROS production.29 However, large clinical trials of antioxidant therapies failed to show protection against cardiovascular diseases. This may be because of the fact that ROS have also been considered as important physiological signaling molecules.1 In that regard, cAMP-independent activation of PKARIα by oxidation15 has been described to be required for ischemia-dependent angiogenesis16 as well as for PDGF-dependent signaling.17 Recently, oxidation of PKARIα was further shown to protect against acute ischemia/reperfusion injury ex vivo, most likely through negative regulation of 2-pore channel-dependent excess Ca release from the lysosome.18 In line with this, we observed acute AngII/ROS-mediated oxidation and translocation of PKARIα to distinct cellular compartments, which included transverse tubules, intercalated discs, as well as the...
Figure 6. Oxidized PKARI\(\alpha\) (protein kinase A type I-\(\alpha\) regulatory subunit) is required to stimulate \(I_{Ca}\) upon transverse aortic constriction (TAC).

A. Original traces for \(I_{Ca}\) measured by whole-cell rupture-patch clamp technique (protocol in the right panel) in isolated ventricular myocytes at baseline and late after TAC (ie, at 6 weeks).

B. Mean data for peak \(I_{Ca}\) voltage relationship at baseline (left panel), at 1 week after TAC (middle panel), and at 6 weeks after TAC (right panel). Peak \(I_{Ca}\) at 0 mV is shown in (C). While \(I_{Ca}\) density was transiently increased in wild-type (WT) at 1 week after TAC and was still maintained at 6 weeks after TAC as compared with baseline, knock-in (KI) cells displayed a lack of \(I_{Ca}\) stimulation at 1 week and a reduction of peak \(I_{Ca}\) at 6 weeks after TAC. Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs baseline. #Indicates significance vs WT. $Indicates significance vs previous phase using 2-way (TW) ANOVA with Holm-Sidak post-test.
nucleus. This corresponds well with our functional observation that oxidized PKARI\(\alpha\) specifically regulates LTCC at the sarcolemmal membrane. It should be noted that Simon et al reported distinct localization of PKARI\(\alpha\) to the lysosomes in their model of untreated cell culture that per se resulted in near-complete PKARI\(\alpha\) disulfide formation. However, distinct stimuli and sources of ROS may differentially influence localization of PKARI\(\alpha\). Here, we used external application of AngII or performed TAC surgery, both of which are known to activate Nox2, which is localized at the cell membrane.\textsuperscript{27,30} Nox2-dependent ROS could have thereby contributed to oxidize PKARI\(\alpha\) at the cell membrane/transverse tubules (ie, in the proximity of the LTCC). In addition, we found evidence that Nox4 may contribute to PKARI\(\alpha\) oxidation following pressure overload as well, because Nox4-deficient hearts subjected to abdominal aortic banding had less dimerized PKARI\(\alpha\) and more monomeric PKARI\(\alpha\) as compared with WT following abdominal aortic banding. This
suggests that different sources and species of ROS (ie, Nox2 and O$_2^-$, respectively, Nox4 and H$_2$O$_2$) may be capable of oxidizing PKARI$\alpha$ upon pressure overload. Because Nox4 is known to exert adaptive signaling upon pressure overload,$^{28}$ oxidized PKARI$\alpha$ could represent a likely downstream signal for Nox4, which warrants further investigation.

Importantly, PKARI$\alpha$ translocation and activation occurred despite comparably elevated levels of ROS and cAMP following TAC. Furthermore, despite absent dimerization of PKARI$\alpha$ in KI mice, global PKA activity was found to be unaffected and the PKA-dependent phosphorylation status of important Ca handling proteins such as at the RyR2 and PLB (at serine 2809 and serine 16, respectively) was not affected. Likewise, we did not observe different expression levels of important Ca handling proteins in WT versus KI hearts during the development of HF that included SERCA2a (SR Ca ATPase 2a), RyR2, PLB, CaMKII, and PKA [C] (protein kinase A, catalytic subunit). These observations collectively indicate that oxidized PKARI$\alpha$ translocates to distinct cellular compartments upon disease-related ROS, where it differentially regulates Ca handling proteins including LTCC.

**Enhanced HF Upon Chronic Pressure Overload Is Attributable to Reduced Peak $I_{\text{Ca}}$ in KI Mice**

To further investigate the role of oxidized PKARI$\alpha$ in cardiac pathology in vivo, WT and KI mice underwent TAC surgery to induce long-term pressure overload as a model of chronic oxidative stress. In the course of HF development following TAC, KI mice showed significantly impaired LV function as compared with WT as early as 1 week after TAC. This early contractile dysfunction in KI mice was evident in the absence of signs of enhanced structural remodeling such as LV or cellular hypertrophy, fibrosis, and reduced capillary density. Hence, we interpret this finding in a way that functional remodeling precedes structural remodeling in KI mice that ultimately appeared late after TAC (ie, at 6 weeks after TAC). On the cellular level, KI myocytes had reduced Ca
transient amplitudes as compared with WT cells at 1 week after TAC, which should have contributed to reduced LV function as observed in vivo. It is well documented that Ca transients in failing myocytes exhibit slowed decay kinetics.\textsuperscript{32,33} Significant prolongation of Ca transient decay upon TAC was observed in our model as well, but with only minor difference between WT and KI and in the face of comparable PLB phosphorylation at serine 16. As already mentioned above, no slowing of Ca transient decay was observed upon acute exposure to AngII, which suggests that PKARI\(\alpha\) is not critically involved in the regulation of PLB and SR Ca reuptake in the context of increased ROS formation. As with acute AngII treatment, Ca spark frequency was similarly increased in the face of a comparable SR Ca content following TAC. This suggests that unlike PKARII (protein kinase A type II regulatory subunit),\textsuperscript{9} oxidized PKARI\(\alpha\) may not be involved in the regulation of SR Ca content and release. Accordingly, PKA-dependent phosphorylation at the RyR2 was similar between groups following TAC. In sharp contrast, peak \(I_{\text{Ca}}\) was greatly and persistently reduced in KI as compared with WT cells throughout TAC-induced HF development. Early after TAC (ie, at 1 week), TAC-related stimulation of peak \(I_{\text{Ca}}\) was present in WT only, which mimics the situation upon acute AngII exposure. Late after TAC (ie, at 6 weeks), peak \(I_{\text{Ca}}\) was normalized to baseline conditions in WT cells, whereas at this point in time, KI cells had significantly reduced peak \(I_{\text{Ca}}\) as compared with baseline. Because SR Ca handling was largely comparable between groups, this observation implies that reduced peak \(I_{\text{Ca}}\) may be the causative mechanism of reduced Ca transient amplitudes and contractility in KI mice following TAC.

Although it remains controversial whether \(I_{\text{Ca}}\) current is reduced in cardiomyocytes from animal models or humans in heart failure,\textsuperscript{34} there is general agreement that \(\beta\)-adrenergic \(I_{\text{Ca}}\) reserve is impaired in HF.\textsuperscript{12} Our data are in contrast to previous studies in animal models of heart disease showing that inhibition of LTCC activity may prevent or even reverse pathological cardiac remodeling and

| Table 2. Baseline |
|------------------|
| Protein         | WT  | KI  | P value |
| SERCA2a         | 1.00±0.44 | 1.49±0.35 | 0.44 |
| LTCC            | 1.00±0.22 | 1.19±0.06 | 0.46 |
| PLB             | 1.00±0.10 | 1.10±0.11 | 0.56 |
| pS16/PLB        | 1.00±0.30 | 0.27±0.28 | 0.61 |
| pT17/PLB        | 1.00±0.13 | 0.69±0.21 | 0.28 |
| RyR2            | 1.00±0.06 | 1.05±0.12 | 0.70 |
| pS2809/RyR2     | 1.00±0.03 | 1.95±0.30 | 0.03 |
| pS2814/RyR2     | 1.00±0.06 | 1.17±0.17 | 0.40 |
| PKA [C]         | 1.00±0.04 | 1.11±0.00 | 0.05 |
| PKAR\(\alpha\) dimer/monomer | 1.00±0.038 | 0.005±0.001 | <0.05* |
| CaMKII          | 1.00±0.15 | 1.01±0.05 | 0.95 |
| pCaMKII         | 1.00±0.07 | 1.09±0.21 | 0.70 |
| oxCaMKII        | 1.00±0.08 | 0.97±0.05 | 0.78 |

CaMKII indicates Ca/calmodulin-dependent protein kinase II; KI, knock-in; LTCC, L-type calcium channel; oxCaMKII, oxidized CaMKII; pCaMKII, phosphorylated CaMKII; PKA [C], protein kinase A, catalytic subunit; PKAR, protein kinase A type I-\(\alpha\) regulatory subunit; PLB, phospholamban; pS16, phosphorylation at serine 16; pS2809, phosphorylation at serine 2809; pS2814, phosphorylation at serine 2814; pT17, phosphorylation at threonine 17; RyR2, ryanodine receptor 2; SERCA2a, sarcoplasmic reticulum Ca-ATPase 2a; and WT, wild-type.

*Indicates significance using Student’s unpaired t-test.

| Table 3. Protein levels at 1 week |
|----------------------------------|
| Protein         | WT  | KI  | P value |
| SERCA2a         | 1.00±0.15 | 0.76±0.19 | 0.37 |
| LTCC            | 1.00±0.29 | 0.89±0.35 | 0.82 |
| PLB             | 1.00±0.41 | 1.50±0.58 | 0.52 |
| pS16/PLB        | 1.00±0.39 | 0.88±0.40 | 0.84 |
| pT17/PLB        | 1.00±0.28 | 0.78±0.45 | 0.70 |
| RyR2            | 1.00±0.03 | 1.10±0.04 | 0.12 |
| pS2809/RyR2     | 1.00±0.39 | 0.99±0.17 | 0.98 |
| pS2814/RyR2     | 1.00±0.21 | 0.95±0.18 | 0.86 |
| PKA [C]         | 1.00±0.04 | 1.22±0.08 | 0.08 |
| PKAR\(\alpha\) dimer/monomer | 1.00±0.197 | 0.002±0.000 | <0.05* |
| CaMKII          | 1.00±0.23 | 0.96±0.11 | 0.90 |
| pCaMKII         | 1.00±0.23 | 0.58±0.19 | 0.23 |
| oxCaMKII        | 1.00±0.23 | 1.04±0.16 | 0.89 |
| TAC, 1 wk       | 1.00±0.15 | 0.92±0.10 | 0.74 |
| PLB             | 1.00±0.14 | 1.36±0.21 | 0.18 |
| pS16/PLB        | 1.00±0.09 | 1.26±0.16 | 0.21 |
| pS2809/RyR2     | 1.00±0.19 | 1.02±0.31 | 0.97 |
| pS2814/RyR2     | 1.00±0.14 | 0.64±0.14 | 0.10 |
| RyR2            | 1.00±0.07 | 1.05±0.06 | 0.57 |
| pS2809/RyR2     | 1.00±0.20 | 1.05±0.12 | 0.84 |
| pS2814/RyR2     | 1.00±0.12 | 0.70±0.08 | 0.06 |
| PKA [C]         | 1.00±0.03 | 1.00±0.02 | 0.99 |
| CaMKII          | 1.00±0.06 | 1.03±0.05 | 0.71 |
| pCaMKII         | 1.00±0.36 | 1.07±0.47 | 0.91 |
| oxCaMKII        | 1.00±0.10 | 1.03±0.11 | 0.83 |
| Troponin        | 1.00±0.34 | 0.69±0.21 | 0.73 |
| pTroponin       | 1.00±0.30 | 0.92±0.26 | 0.84 |

CaMKII indicates Ca/calmodulin-dependent protein kinase II; KI, knock-in; LTCC, L-type calcium channel; oxCaMKII, oxidized CaMKII; pCaMKII, phosphorylated CaMKII; PKA [C], protein kinase A, catalytic subunit; PKAR\(\alpha\), protein kinase A type I-\(\alpha\) regulatory subunit; PLB, phospholamban; pS16, phosphorylation at serine 16; pS2809, phosphorylation at serine 2809; pS2814, phosphorylation at serine 2814; pT17, phosphorylation at threonine 17; RyR2, ryanodine receptor 2; SERCA2a, sarcoplasmic reticulum Ca-ATPase 2a; and WT, wild-type.

*Indicates significance using Student’s unpaired t-test.
hypertrophy. Moreover, upregulation of I_{Ca} by enhanced expression of the β subunit β2a has been shown to result in cardiac damage. The latter, however, resulted in an artificial basal increase in I_{Ca} by 50% with enhanced contractility, mitochondrial Ca overload, and cellular necrosis.

Clinical trials, on the other hand, have not only failed to show a clinical benefit of Ca channel blockers but also resulted in worsening HF and increased mortality.

The mechanistic relationship between impaired L-type Ca current and HF has recently been investigated in more detail. Heterologous knock-out of Ca_{1.2} in mice resulted in a 40% reduction in peak I_{Ca} density, which led to an age-dependent progressive decline of fractional shortening and LV enlargement assessed by echocardiography in vivo. This effect correlated with the magnitude of reduction in Ca_{1.2} expression. The smaller the expression of Ca_{1.2}, the more severe was the reduction in fractional shortening, the more pronounced was the enlargement of LV volume and the higher was the mortality in these mice. Moreover, mice with heterologous knock-out of Ca_{1.2} exhibited enhanced HF development upon TAC, which strikingly resembles the data from the present study. Thus, our study is consistent with clinical data showing that inhibition of LTCC may be detrimental in HF and adds to the growing body of evidence that L-type Ca current is a major regulator of excitation–contraction coupling not only in healthy myocardium but also in HF.

Pharmacological Stimulation of Peak I_{Ca} Using Bay K8644 Acutely Rescues Ca Transients Amplitudes in AngII-Treated Cardiomyocytes and LV Function in Failing KI Mice

The crucial relevance of I_{Ca} for ECC in KI is further supported by our observation that acute pharmacological stimulation of I_{Ca} with Bay K8644 restored Ca transients in AngII-treated KI myocytes and rescued LV function in failing KI mice after TAC. This corroborates the importance of I_{Ca} to maintain cardiac contractility upon oxidative stress and underscores the crucial role of oxidized PKA\textsubscript{R\alpha} to stabilize Ca transients and thereby cardiac contractility via I_{Ca} stimulation. Pump failure may also be the leading cause of increased mortality in KI mice that dramatically increased from 4 weeks after TAC, when structural remodeling also became manifest. Ventricular arrhythmias, on the other hand, were induced to a similar extent in WT and KI mice following TAC. In that regard, the activity and expression of CaMKII, a key regulator of arrhythmogenesis in HF, was similar in WT and KI mice.

Increased Phosphorylation of the \( \alpha \) Subunit of LTCC \( \text{Ca}_{1.2} \) as a Potential Mechanism of \( I_{\text{Ca}} \) Regulation by Oxidized PKA\textsubscript{R\alpha}

To date, the role for PKA\textsubscript{R\alpha} in the heart is poorly described. In contrast, PKA\textsubscript{R\alpha}, which is known to bind

| Protein | WT | n | KI | n | \( P \) value |
|---------|----|---|----|---|------------|
| SERCA2a | 1.00±0.28 | 4 | 1.25±0.48 | 3 | 0.41 |
| PLB     | 1.00±0.34 | 4 | 0.96±0.55 | 3 | 0.91 |
| pS16/PLB| 1.00±0.34 | 4 | 0.57±0.22 | 3 | 0.14 |
| RyR2    | 1.00±0.21 | 3 | 0.98±0.20 | 3 | 0.91 |
| pS2809/RyR2| 1.00±0.23 | 3 | 1.36±0.05 | 2 | 0.13 |
| PKA [C] | 1.00±0.11 | 3 | 0.93±0.04 | 2 | 0.46 |
| PKAR\textsubscript{R\alpha} dimer/monomer | 1.00±0.37 | 4 | 0.05±0.02 | 4 | <0.05* |
| CaMKII | 1.00±0.22 | 3 | 1.02±0.13 | 2 | 0.91 |
| pCaMKII | 1.00±0.42 | 3 | 1.68±0.56 | 2 | 0.21 |

CaMKII indicates Ca/calmodulin-dependent protein kinase II; KI, knock-in; pCaMKII, phosphorylated CaMKII; PKA [C], protein kinase A, catalytic subunit; PKAR\textsubscript{R\alpha}, protein kinase A \( \text{type I-\alpha regulatory subunit} \); PLB, phospholamban; pS16, phosphorylation at serine 16; pS2809, phosphorylation at serine 2809; RyR2, ryanodine receptor 2; SERCA2a, sarcoplasmic reticulum Ca-ATPase 2a; TAC, transverse aortic constriction; and WT, wild-type.

*Indicates significance using Student’s unpaired t-test.

Table 4. Protein levels at 6 weeks

Figure 8. Pharmacological stimulation of I_{Ca} (L-type Ca current) using Bay K8644 restores Ca transients in AngII (angiotensin II)-treated knock-in (KI) myocytes and rescues left ventricular dysfunction in failing KI mice following transverse aortic constriction (TAC).

A. Original traces (A) of intracellular Ca transients measured in Fura-2 loaded ventricular myocytes from wild-type (WT) (upper panel) and KI mice (lower panel) in the absence (left) and presence of 1 μmol/L Bay K8644 (right). \( F_{\text{SAC}}/F_{\text{SBG}} \) indicates the fluorescence intensity ratio measured with Fura-2. Although Ca transients were significantly reduced in KI cells upon sole AngII treatment (left), addition of Bay K8644 induced a significant increase in Ca transients amplitude in both groups that was significantly more pronounced in KI cells (right). Average data for (A) are depicted in (B). Data are normally distributed (Shapiro-Wilk test). *Indicates significance vs AngII control using 2-way (TW) ANOVA with Holm-Sidak post-test. C. Original M-mode traces of WT (upper panel) and KI mice (lower panel) after TAC and following acute stimulation of I_{Ca} using Bay K8644. Average data in (D) demonstrate a significantly enhanced inotropic response in KI mice following acute stimulation of I_{Ca} using Bay K8644. Data are normally distributed (D’Agostino-Pearson test). 4Indicates significance vs WT using unpaired t test. LVEF indicates left ventricular ejection fraction.
to A-kinase anchoring proteins that determine its substrate specificity, has been shown to be involved in phosphorylation and regulation of important cardiac ion channels and transporters. Among them are LTCC and PLB. PKA-dependent phosphorylation of the α subunit of LTCC CaV1.2 has been shown to stimulate I_{Ca,L} [41-47]. PKA-dependent phosphorylation of PLB at serine 16 results in dissociation of this repressor from
SR Ca ATPase, which stimulates SR Ca reuptake.9 Our study indicates that enhanced ROS production leads to PKARIα oxidation and PKARIα-dependent stimulation of ICa. Interestingly, Ca1,2 expression levels did not change; thus, the stimulation of peak ICa was most likely because of altered ICa gating, which is consistent with the observed increase in phosphorylation of Ca1,2 at serine 1928. The role of PKARIα for the regulation of ICa gating was further corroborated by our observation that acute AngII exposure increased peak ICa density in WT myocytes in parallel to PKARIα dimerization (no masking hypertrophy), which was completely absent in KI myocytes.

In contrast, mice lacking oxidative activation of PKARIα had no stimulation of ICa early after TAC and showed dramatically reduced ICa density late after TAC, which was in line with reduced phosphorylation of Ca1,2 at serine 1928.

Interestingly, the involvement of serine 1928 in the PKA-dependent regulation of LTCC has been suggested before.42 Many authors have reported that serine 1928 is readily phosphorylated by PKA and can be used as a measure of PKA-dependent Ca1,2 phosphorylation.43 However, other reports have questioned the role of serine 1928 but confirmed the importance of the C-terminal region of Ca1,2.41 Importantly, all these reports have investigated ICa stimulation by either direct or indirect increase of cytoplasmic CAMP (forskolin, isoproterenol) or application of cAMP mimetics (8-Br-cAMP). Thus, they have investigated the cAMP-dependent and not the ROS-dependent stimulation of ICa. Beside serine 1928, other PKA phosphorylation sites even outside of the C-terminus (ie, serine 1142,44 serine 1700,45 and serine 182946) have also been suggested. Thus, identification of the exact PKARIα-specific phosphorylation site that is responsible for the functional alteration of ICa warrants further investigation but is beyond the scope of the present study.

Limitations
Our study has several important limitations that need to be considered. First, although our study adds evidence that PKARIα acutely translocates to the sarcolemmal membrane upon oxidative stress, which is associated with increased phosphorylation of the LTCC and augmented ICa (see above), we did not establish a clear protein–protein interaction here, and did not investigate the association of oxidized PKARIα with other compartments such as the lysosomes and lysosomal Ca handling. Second, we cannot exclude that oxidative activation of PKARIα is actually because of a thiol/disulfide exchange reaction only remotely associated with ROS. Third, although it appears tempting to speculate that stimulation of ICa could serve as a treatment option for HF associated with increased oxidative stress, the long-term effects of inotropic stimulation using Bay K8644, which would likely increase potentially harmful oxygen consumption, have not been subjects of the current study. Finally, although we present clear evidence of an acute relevance of oxidized PKARIα for ICa gating (such as upon AngII), we cannot exclude that there may be only a narrow time window during which oxidative PKARIα activation would be relevant, with all long-term effects following TAC being secondary to this acute regulation. We observed a biphasic behavior of the PKARIα dimer to monomer ratio in WT mice following TAC with a transient increase during the early stage after TAC (ie, at 1 week) and a normalization to baseline conditions late after TAC (ie, at 6 weeks). However, this may be also influenced by altered antioxidants levels in HF that were not investigated here.

CONCLUSIONS
Our study demonstrates the following: (1) PKARIα is oxidized in the myocardium of mice subjected to TAC or in myocytes acutely exposed to AngII, both conditions of increased ROS production. (2) Oxidation of PKARIα is critically involved in the regulation of L-type Ca current possibly by phosphorylation. (3) Mice that lack oxidative activation of PKARIα develop enhanced LV contractile dysfunction because of reduced Ca transient amplitude and have increased mortality upon TAC. Thus, oxidative activation of PKA may be required for the heart to adapt to increased workload. This should be carefully considered when using antioxidant treatment for heart failure.

ARTICLE INFORMATION
Received April 19, 2021; accepted July 15, 2021.

Affiliations
Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany (M.M.I., D.T., M.T., S.L., J.M., H.D., J.M., S.P., S.S., L.S.M., C.M.S., S.W.); Department of Biochemistry and Molecular Biology, University of Dhaka, Bangladesh (M.M.I.); School of Cardiovascular Medicine & Sciences, Kings College London British Heart Foundation Centre of Excellence, London, United Kingdom (M.Z., A.M.S.); Department of Pharmacology and Toxicology, Technical University Dresden, Dresden, Germany (A.E.); Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Eppendorf, Germany (V.O.N.); and The William Harvey Research Institute, . Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom (P.E.).

Acknowledgments
The authors acknowledge the expert technical assistance of T. Sowa, F. Radtke, and T. Schulte. The authors also thank Drs Schäfer and Gogiraju for their cooperation during the study.

Sources of Funding
This work was supported by International Research Training Group GRK 1816 of the Deutsche Forschungsgemeinschaft (DFG) to S.W. and L.S.M.
REFERENCES

1. Wagner S, Rokita AG, Anderson ME, Maier LS. Redox regulation of sodium and calcium handling. Antioxid Redox Signal. 2013;18:1063–1077. DOI: 10.1089/ars.2012.4818.

2. Sag CM, Wagner S, Maier LS. Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic Biol Med. 2013;63:338–349. DOI: 10.1016/j.freeradbiomed.2013.05.035.

3. Gill JS, McKenna WJ, Camm AJ. Free radicals irreversibly decrease Ca2+ currents in isolated guinea-pig ventricular myocytes. Eur J Pharmacol. 1995;292:337–340.

4. Morris TE, Sulakhe PV. Sarcoplasmic reticulum Ca(2+)- pump dysfunction. J Am Heart Assoc. 2015;6:7920.

5. Eisel F, Boosen M, Beck M, Heide H, Wittig I, Beck KF, Pfeilschifter J. Platelet-derived growth factor triggers PKA-mediated signaling by a redox-dependent mechanism in rat renal mesangial cells. Biochem Pharmacol. 2013;85:101–108. DOI: 10.1016/j.bcp.2012.10.017.

6. Simon CN, Vrellaku B, Monterisi S, Chu SM, Rawlings N, Lomas O, Marchal GA, Watthe D, Syeda F, Gajendragadkar PR, et al. Oxidation of protein kinase A regulatory subunit PKAβI protects against myocardial ischemia-reperfusion injury by inhibiting lysosomal-triggered calcium release. Circulation. 2011;124:449–456. DOI: 10.1161/CIRCULATIONAHA.110.246781.

7. Mitchell GF, Joren A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 1998;274:H747–H751. DOI: 10.1152/ajpheart.1998.274.3.H747.

8. Sag CM, Schneele M, Zhang J, Murdoch CE, Kossmann S, Protti A, Santos CXC, Sawyer G, Zhang X, Mongue-Dinh H, et al. Distinct regulation of myeloid cell and endothelial cell NAPDH oxidase 2 on blood pressure. Circulation. 2017;135:2183–2177. DOI: 10.1161/CIRCULATIONAHA.116.023877.

9. Mitchell GF, Joren A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 1998;274:H747–H751. DOI: 10.1152/ajpheart.1998.274.3.H747.

10. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ. FRET measurements of intracellular Ca2+ concentrations and Ca2+ analog permeability in intact cells. Nat Protoc. 2014;9:427–438. DOI: 10.1038/nprot.2010.198.

11. Mitchell GF, Joren A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 1998;274:H747–H751. DOI: 10.1152/ajpheart.1998.274.3.H747.

12. Chen Y, Saulnier JL, Furukawa S, Goldman B, Margulies KB, Sabatini BL. A PKA activity sensor for quantitative analysis of endogenous GPCR signaling via 2-photon FRET-FLIM imaging. Front Pharmacol. 2014;5:56. DOI: 10.3389/fphar.2014.00056.

13. Griev DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, Shah AM. Involvement of the nicotinamide adenine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol. 2008;47:817–826. DOI: 10.1016/j.jcmg.2006.09.051.

14. Eisel F, Boosen M, Beck M, Heide H, Wittig I, Beck KF, Pfeilschifter J. Platelet-derived growth factor triggers PKA-mediated signaling by a redox-dependent mechanism in rat renal mesangial cells. Biochem Pharmacol. 2013;85:101–108. DOI: 10.1016/j.bcp.2012.10.017.

15. Tinscher K, Rokita AG, Unsold B, Zuh W, Karagias G, Sossalla S, Reuter SP, Becker A, Teucher N, Seidler T, et al. Cardiac redox remodeling in preload versus afterload. Circulation. 2010;122:993–1003. DOI: 10.1161/CIRCULATIONAHA.110.943431.

16. Tinscher K, Rokita AG, Unsold B, Zuh W, Karagias G, Sossalla S, Reuter SP, Becker A, Teucher N, Seidler T, et al. Cardiac redox remodeling in preload versus afterload. Circulation. 2010;122:993–1003. DOI: 10.1161/CIRCULATIONAHA.110.943431.
34. Richard S, Leclercq F, Lemaire S, Plott C, Nargeot J. Ca(2+)-currents in compensated hypertrophy and heart failure. Circ Res. 1998;37:300–311. DOI: 10.1161/01.RES.97.4.376.

35. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Asanuma H, Minamino T, Tomoike H, Hori M, Kitakaze M. Bendipidine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. Cardiovasc Res. 2005;65:379–386. DOI: 10.1016/j.cardiores.2004.11.006.

36. Seminarsian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Mende U, Marks AR, Kass DA, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002;109:1013–1020. DOI: 10.1172/JCI200214477.

37. Nakayama H, Chen X, Baines CP, Klevisky R, Zhang X, Zhang H, Jaleel N, Chua BHL, Hewett TE, Robbins J, et al. Ca(2+)- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431–2444. DOI: 10.1172/JCI31060.

38. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1998;339:385–392.

39. Goonasekera SA, Hammer K, Auger-Messier M, Bodi I, Chen X, Zhang X, Zhang H, Jaleel N, Chua BHL, Hewett TE, Robbins J, et al. Ca(2+)- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431–2444. DOI: 10.1172/JCI31060.

40. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, Anderson ME, Grandi E, Bers DM, Backs J, et al. Reactive oxygen species-activated Ca/calmodulin kinase IIdelta is required for late postischemic cardiomyocyte death. J Biol Chem. 2013;288:25525–25534. DOI: 10.1074/jbc.M113.483132.

41. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, et al. Oxidized Ca(2+)/calmodulin-dependent protein kinase. Biochemistry. 1996;35:10392–10402.

42. De Jongh KS, Murphy BJ, Colvin AA, Hell JW, Takahashi M, Catterall WA. Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3’,5’-cyclic monophosphate-dependent protein kinase. Biochemistry. 1996;35:10392–10402.

43. Erxleben C, Gomez-Alegria C, Darden T, Mori Y, Bimbaumer L, Armstrong DR. Modulation of cardiac Ca(V)1.2 channels by dihydropyridine and phosphatase inhibitor requires Ser-1142 in the domain III pore loop. Proc Natl Acad Sci USA. 2003;100:2929–2934. DOI: 10.1073/pnas.2628046100.

44. Fuller MD, Emrick MA, Sadilek M, Scheuer T, Catterall WA. Molecular mechanism of calcium channel regulation in the fight-or-flight response. Science Signal. 2010;3:ra70. DOI: 10.1126/scisignal.2001152.

45. Takahashi E, Fukuda K, Miyoshi S, Murata M, Kato T, Ito M, Tanabe T, Ogawa S. Leukemia inhibitory factor activates cardiac L-type Ca(2+) channels via phosphorylation of serine 1829 in the rabbit Cav1.2 subunit. Circ Res. 2004;94:1242–1248.

46. Weiss S, Oz S, Benmoche A, Dascal N. Regulation of cardiac L-type Ca(2+)-channel currents by the alpha1B2 calcium channel. J Biol Chem. 2007;282:22024–22035. DOI: 10.1074/jbc.M607899200.

47. Picht E, Zima AV, Blatter LA, Bers DM. SparkMaster: automated calcium spark analysis with ImageJ. Am J Physiol Cell Physiol. 2007;293:C1073–C1081. DOI: 10.1152/ajpcell.00586.2006.
Supplemental Material
Supplemental Methods

**In vivo procedures**

**Generation of Cys17Ser PKA RI and Epac1-camps mice**

Mice that constitutively express PKA RI Cys17Ser (KI) were generated as previously described. The point mutation Cys17Ser was introduced into exon 1 of the in Prkar1a gene by site-directed mutagenesis. These mice behave normally under physiologic conditions. To detect cAMP levels in cardiomyocytes, transgenic mice that ubiquitously express cAMP sensor (Epac1-camps) were generated as previously described. The cAMP sensor comprises a cAMP binding domain derived from Epac1 which is controlled by a CAG promoter. The behavior of these transgenic mice is natural under physiologic conditions.

**Transverse aortic constriction**

Male mice at the age of 11–13 weeks (20–25 g) were anaesthetized by intraperitoneal injection of medetomidin 0.5 mg/kg (body weight, WB), midazolam 5 mg/kg BW and fentanyl 0.05 mg/kg BW. Additionally, an intraperitoneal injection of buprenorphine at 0.06 mg/kg BW was given at least half an hour before surgery. At the end of surgery, anesthesia was antagonized using intraperitoneal injections of atipamezol (2.5 mg/kg BW), flumazenil (0.5 mg/kg BW) and buprenorphine (0.1 mg/kg BW). Body temperature was maintained at 36–37 °C using a warm pad (Mousepad, THM 100, Indus Instruments, Webster, USA) and continuously monitored by a rectal probe. In addition, daily oral treatment with 1.33 mg/ml metamizole in the drinking water starting 2 days before the surgery until 5 days after surgery was conducted. For transverse aortic constriction, a small incision was made into the skin above the upper thoracic inlet (~1 cm) and thyroids were lifted gently. Then, the muscle underneath the incision was carefully opened with pointed bent tweezers above and along the trachea. By cautiously cutting the sternum and moving the thymus apart, the transverse aorta was exposed. After separating the connective tissues, a 6-0 non-absorbable suture was used to form a knot between right and left carotid artery. The knot was tightened against a 27G cannula. Thereafter, sternum and skin were carefully stitched to ensure full recovery after the operation. Using this procedure, a 65–70% constriction (outer diameter, 0.3 mm) could be introduced. For control, a sham procedure was conducted applying a similar surgical procedure but without constriction of the aorta. Sham-operated mice had normal survival and did not develop HF. Echocardiographic data of sham operated mice are given in Table 1.

**Echocardiography**

Echocardiography was performed on anesthetized mice (isoflurane 1.5%, spontaneous respiration) at different time points (i.e. at baseline, at 1 week after TAC and at 6 weeks after TAC, respectively) by experienced ultrasonographers who were unaware of the mice’s treatment details. After shaving
the anterior chest, mice were placed onto a warming pad and body temperature was continuously monitored by a rectal probe. Raw data were acquired using a 30 MHz linear array transducer. The transducer was coupled to a Vevo 2100 imager (FUJIFILM Visual Sonics, Toronto, Canada). Short-axis, 2-dimensional echocardiographic images were acquired at papillary muscle level at a frame rate of about 300 Hz. Short-axis M-mode images were obtained at a sweep speed of 100 mm/s from the same anatomic position for 5 seconds. Long axis images included the left ventricular apex. Thicknesses of the septum, the anterior and posterior myocardial wall, the inner diameter of the left ventricle (LVEDD) and the area of the left ventricular cavity were measured in systole (sys) and diastole (dia) from the short axis view according to standard procedures. Systolic and diastolic left ventricular volumes were calculated using the area-length method and the ejection fraction was derived. In some experiments, $I_{Ca}$ was pharmacologically stimulated using 100 mg Bay K8644 i.p (Sigma Aldrich Co., St. Louis, MO, USA) in anesthetized WT and KI mice undergoing echocardiography at 1 week after TAC. The maximum of the acute inotropic response (i.e. a Bay K8644-dependent change in LVEF) was reached at ~6 mins post Bay K8644 injection and was therefore taken for analysis. All image analysis was performed offline using Vevolab analysis software (Version 1.7).

Electrophysiological studies

Mice were anaesthetized with isoflurane and kept on a warm pad as mentioned above. After a rest period of 5 min at a supine position on the pad, a baseline surface ECG (lead II) was acquired by subcutaneously placing 27-gauge needles in each limb of mice. The electrodes were connected to a Bio-Amplifier and a multichannel data acquisition system (Powerlab 16/30, AD Instruments, Colorado Springs, USA). The data was stored using Labchart Pro software, version 7 (AD Instruments, Colorado Springs, USA). QT intervals were heart rate corrected (QTc) using Mitchell’s formula. The midline cervical incision was made to expose the right external jugular vein, and a catheter (Millar 1.1F octapolar EP catheter, EPR-800; Millar Instruments) was inserted from the external jugular vein into the right ventricle (RV), so that the top of the catheter attained the RV inferior diaphragmatic wall. The catheter was also connected to the multichannel data acquisition system (Powerlab 16/30) and 4 intra-cardiac bipolar electrograms were recorded. The proximal and distal pairs of electrodes were used for recording and pacing the right atrium (RA) and RV. A standard clinical EPS protocol was employed to determine electrophysiological parameters. In brief, right atrial or ventricular pacing was performed using 2 ms current pulses delivered by an external stimulator (STG-3008; Multi Channel Systems). Inducibility of ventricular arrhythmias was tested by decremental burst pacing. Burst pacing started at a 40 ms cycle length, decreasing by 2 ms every 2 s to a cycle length of 20 ms. Burst pacing was repeated one min after the previous burst concluded or the termination of arrhythmias. Burst pacing was performed for a total of five times for ventricular stimulation, respectively. Ventricular tachycardia (VT) were defined as rapid ventricular potentials that occurred independent from atrial potentials and displayed altered QRS morphology. If a VT sustained for more
than 1 second, it was considered as relevant and used for inducibility analysis. At the end of the experiments, mice were killed by cervical dislocation under anesthesia.

**Blood pressure measurements**

AngII (1.0 mg·kg\(^{-1}\)·d\(^{-1}\)) was administered for 14 days via subcutaneous osmotic minipumps (model 1002, Alzet, Cupertino, CA) implanted under 2% isoflurane as described previously.\(^{22}\) Mean blood pressure was assessed using the CODA mouse rat tail-cuff system (Kent Scientific). We allowed mice to acclimatize to a clear acrylic tube with a nose cone holder (Kent Scientific) for at least half an hour before BP recordings were started. Mean BP was assessed at baseline and following 14 days of AngII treatment. A minimum of 20 BP recordings was averaged for each mouse.

**In vitro experiments**

**Isolation of mouse ventricular myocytes**

Ventricular cardiomyocytes were isolated according to established enzymatic procedure as previously described.\(^{23}\) Only adult male mice aged 10-20 weeks were used.

**Measurement of intracellular Ca**

Intracellular Ca transients were measured as described previously.\(^{5}\) Briefly, myocytes on laminin-coated recording chambers were loaded with 10 µmol/L Fura-2-AM in the presence of 0.02% (w/v) pluronic acid (Molecular Probes, Eugene, OR) for 20 min, at room temperature in the dark. The chambers were mounted on the stage of an inverted microscope (Nikon Eclipse TE2000-U) and superfused with Tyrode solution (37°C) containing (in mmol/L) 140 NaCl, 5.4 KCl, 1 MgCl\(_2\), 5 HEPES, 10 glucose, 1 CaCl\(_2\), pH 7.4. After 10 min of washing out the external dye, myocytes were field-stimulated (voltage 20% above threshold) at various basic cycle lengths. Intracellular Fura-2 was excited at alternating wavelengths of 340 and 380 nm, emitted epifluorescence was monitored at 510 nm (F\(_{340}\) and F\(_{380}\)). In some experiments, myocytes were exposed to Ang II (1 µmol/L) for 15 min. All fluorescence emission was recorded using IonWizard software (IonOptix Corporation, Boston, MA). Background fluorescence was subtracted and the ratio F\(_{340}/F_{380}\) was calculated. For Fura-2 measurements, a CCD camera was used to simultaneously record sarcomere length as a function of time. For each pacing frequency, Ca transients were averaged (typically 30 traces) during steady state and analyzed using IonWizard software. For some experiments, caffeine (10 mmol/L) was applied to induce rapid SR Ca\(^{2+}\) release. PKA was inhibited using 5 µmol/l of H89. In another set of experiments, AngII pretreated cells were acutely exposed to 1 µmol/L of Bay K8644.
Measurement of Ca sparks via confocal microscopy

Isolated ventricular myocytes were loaded with 10 µmol/L fluo-4 acetoxymethylester (Molecular Probes; for 12 min at room temperature) and mounted on an inverted laser scanning confocal microscope (Zeiss Pascal 5). Regular myocyte contraction was elicited by electrical field stimulation (1 Hz). For measuring Ca sparks, line scans (512 pixel of 0.075 µm size, 1309 lines per second, 10000 lines per scan, 488 nm excitation, 505 nm long pass emission filter) were acquired immediately after stop of electrical field stimulation. Ca spark characteristics were analyzed using Image J (Sparkmaster plugin). Ca spark frequency (CaSpF) was measured as number of sparks per cell volume and time (100 µm⁻¹s⁻¹).

Measurement of intracellular ROS production

For the measurement of cytosolic ROS production, freshly isolated ventricular myocytes were loaded with the cytosolic ROS indicator CellROX (5 µmol/L for 20 min at room temperature in the dark, Molecular Probes) and then mounted on an inverted laser scanning confocal microscope (Zeiss Pascal 5). After washing the chamber two times for 5 min using Tyrode solution (37°C) containing (in mmol/L) 140 NaCl, 5.4 KCl, 1 MgCl₂, 5 HEPES, 10 glucose, 1 CaCl₂, pH 7.4, CellROX dye was excited at 555 nm and emission was monitored with a long pass filter of 560 nm. In some experiments, myocytes were exposed to AngII (1 µmol/L) for 15 min. Once every minute, CellROX emission was measured and normalized to the basal fluorescence (F₀) for further comparison.

Patch-Clamp Experiments

Ruptured-patch whole-cell voltage-clamp was used to measure I_{Ca}. In all experiments, myocytes were mounted on the stage of a microscope (Nikon Eclipse TE2000-U). For I_{Ca} measurements, microelectrodes (2-3 MΩ) were filled with (in mmol/L) 86 CsCl, 40 Cs-glutamate, 0.92 MgCl₂, 5 Mg-ATP, 0.3 Li-GTP, 10 HEPES, 5 EGTA and 1.8 CaCl₂ (free [Ca²⁺]i 100 nmol/L) (pH 7.2, CsOH). The bath solution contained (in mmol/L) 140 NaCl, 4 CsCl, 1 MgCl₂, 10 glucose, 10 HEPES, 1 CaCl₂ (pH 7.4, CsOH). For I_{Ca}, access resistance was <8 MΩ. Liquid junction potentials were corrected with the pipette in the bath. Fast capacitance was compensated in cell-attached configuration. Membrane capacitance and series resistance were compensated after patch rupture. Signals were filtered with 2.9 and 10 kHz Bessel filters and recorded with an EPC10 amplifier (HEKA Elektronik). Recordings were started 2-3 min after rupture. All experiments were conducted at room temperature.

Measurement of cAMP levels using FLIM-FRET

Quantification of intracellular cAMP generation was performed in isolated adult ventricular Epac1-camps-transgenic mouse cardiomyocytes from sham vs. TAC-operated mice using Fluorescence-Resonance Energy Transfer (FRET). As previously described intracellular cAMP concentration can be traced back to a change in Epac1-camps FRET signal. However, the spectral separation of two fluorescence emissions cannot be carried out with absolute precision when using the
conventional ratiometric measurement of FRET on an inverted fluorescence microscope. Therefore, we applied a more accurate approach to measure FRET signal by fluorescence lifetime imaging microscopy (FLIM). After isolation myocytes were placed on a laminin-coated recording chamber which was mounted on a specialized confocal microscope (Becker & Hickl GmbH; DCS-120). Every 60 seconds an image of the chosen myocyte was recorded for a total of 14 minutes. Starting minute 3, Forskolin (50µM) was applied to induce maximum stimulation of cAMP generation. Imaging data were collected and analyzed using SPCImage, Version 6.4, Becker & Hickl GmbH.

Assessment of cardiac cAMP concentration and PKA activity

In order to study the effect of TAC on cAMP concentration and PKA activity in cardiac tissue samples, a cAMP ELISA kit (Enzo Life Sciences, Lausen, Switzerland) and a PKA Kinase activity Assay (ab139435, Abcam, Berlin, Germany) were performed according to manufacturer’s protocol.

Histology

Cardiac samples were immediately fixed in formalin and embedded in paraffin according to standard procedures. Then, 4 µm sections were stained with antibodies directed against wheat germ agglutinin (WGA, Alexa Fluor™ 594, Life Technologies Corporation, Eugene, OR, USA) and biotinylated Griffonia (Bandeiraea) Simplicifolia Lectin I (Isolectin B4, Vector Laboratories, Inc., Burlingame, CA, USA). Concentrations used for WGA staining were 1:300 and 1:200 for Isolectin B4, respectively. Primary staining was visualized using respective secondary antibody conjugated to Streptavidin (Alexa FlourTM 488, Invitrogen, Carlsbad, CA, USA) and making use of the DAPI substrate (Molecular Probes, Eugen, OR, USA). The cross-sectional area and density of capillaries were averaged from 10 images of left ventricle sections at a magnification of 400x. Only cardiomyocytes with visible nucleus were measured for determination of cross-sectional area. Capillaries were counted in every image and expressed as density/mm². To quantify cardiac fibrosis, the Trichrome Stain (Masson) Kit was used (Sigma Aldrich Co., St. Louis, MO, USA). For this purpose, the whole heart was photographed in single image sections at a magnification of 200x. All images were acquired on a Zeiss Axiostar plus microscope using the Axio Vision 4.9.1. software (Carl Zeiss Microscopy GmbH, Jena, Germany). Morphometric analysis was performed using Histo Quest software (TissueGnostics GmbH, Vienna, Austria). All data were analyzed by one observer blinded to mouse genotypes.

Western blot analysis

Isolated cardiomyocytes and whole mouse heart samples were used for western blot analysis. Cardiomyocytes were plated on culture dishes and exposed to either vehicle or AngII (1 µmol/L, 10 min) and immediately snap frozen. Similarly, after sacrificing the mice, hearts were stored in liquid nitrogen. Samples were then lysed in Tris buffer containing (in mmol/L) 20 Tris-HCl, 200 NaCl, 20 NaF, 1 Na₃VO₄, 1% Triton X-100, 1 DTT (pH 7.4) along with complete protease inhibitor cocktail and
PhosSTOP phosphatase inhibitor cocktail (both Roche Diagnostics) by trituration. In another protocol, (in mmol/L) 100 Tris-HCl pH 7.4, 0.1 EDTA, 100 Maleimide and complete protease inhibitor cocktail were used. After heat denaturation, proteins were separated on 10% in house or 4-20% Bio-rad SDS-polyacrylamide gels. Proteins were then transferred either wet or semi dry methods to a nitrocellulose or PVDF membrane depending on target proteins. Membranes were then blocked with blocking buffer and incubated with primary antibodies: rabbit polyclonal anti-phospho-serine-1928-LTCC α1 (1:10000, Badrilla), rabbit polyclonal anti-LTCC (1:5000), rabbit polyclonal anti-RyR2 (1:20000, Sigma Aldrich), rabbit polyclonal anti-phospho-serine2814-RyR2 (1:6000, Badrilla), rabbit polyclonal anti-phospho-serine2808-RyR2 (1:1000, Badrilla), rabbit polyclonal anti-phospho-serine16-PLB (1:10000, Badrilla), rabbit polyclonal anti-phospho-threonine17-PLB (1:1000, Badrilla), mouse monoclonal anti-PLB (1:15000, Millipore), rabbit polyclonal anti-phospho-Thr286-CaMKII (1:1000, PhosphoSolution), rabbit polyclonal anti-ox-Met281/282-CaMKII (1:1000, GeneTex), anti-CaMKII (1:12000, kindly provided by Prof. Donald Bers, UC Davis, USA), monoclonal anti-regulatory-subunit-type-1-(R)-specific PKA antibody (1:500, BD Transduction Laboratories), mouse monoclonal anti-catalytic PKA [C] antibody (1:10000, BD Transduction Laboratories), rabbit anti-phospho-serine23/24-troponin I (1:2500, Cell signaling), rabbit polyclonal anti-troponin I (1:2500, Cell signaling), mouse monoclonal anti-SERCA (1:20000, Thermo Scientific), and mouse monoclonal anti-GAPDH (1:30000, Biotrend) at 4°C overnight. Secondary antibodies were HRP-conjugated goat anti-rabbit IgG (1:20000, 111-035-144, Jackson lab) and goat anti-mouse IgG (1:20000, 115-035-062, Jackson lab). Secondary antibodies were incubated with membrane for 1 h at room temperature. For the chemiluminescent detection, Immobilon Western Chemiluminescent HRP Substrate (Millipore) was used. Please note that immunoblots were performed under non-reducing conditions when assessing the PKARIα dimer/monomer ratio and CaMKII Met281/282 oxidation, respectively.

As previously described by Simon et al., we also observed a non-specific band above the PKARIα monomer band that was not used for analysis.

**Statistics**

All data are expressed as mean ± SEM. Western blot images were analyzed using Image J v1.5 software. Epifluorescence data were analyzed using IonWizard v6.4. Patch clamp data were analyzed using PatchMaster v2. Electrical programmed stimulation data were analyzed using LabChart 7.0 software. Echocardiographic data were analyzed using Vevolab v1.7 software. All the data were transferred to Microsoft Excel and GraphPad Prism or SigmaPlot 12.5 software. Statistical analyses were performed using GraphPad Prism 9 software or SigmaPlot 12.5. Normality of data was tested by hierarchical application of D'Agostino-Pearson, Shapiro-Wilk, or Kolmogorov-Smirnov test, respectively, depending on the number of experiments. For some experiments, data were transformed (log, reciprocal) to demask a normality distribution prior to normality and statistical testing. If data were not normally distributed or the sample size was too small for normality testing, non-parametric test were used. For longitudinal data, 2-way repeated-measures ANOVA or mixed-effects analysis
was performed; where appropriate, a one-way ANOVA or Kruskal-Wallis test with multiple comparison tests was used. For categorical data, Fisher's exact test was used. Otherwise, Student's unpaired t-test was applied. Two-sided \( P<0.05 \) was considered significant. The method of analysis for each dataset is given in the figure legends. For analysis of \( I_{Ca} \) steady-state activation, data were fitted to a standard Boltzmann equation: 

\[
h_\infty = \frac{1}{1 + \exp \left\{ (V_{1/2} - V)/k_\infty \right\}}
\]

where \( V_{1/2} \) is the membrane potential for half-maximal activation and \( k_\infty \) is a slope factor indicating the slope in e-folds per \( k_\infty \) mV as described by Bers.\(^9\)
Electrocardiographic parameters measured in resting mice at baseline and after TAC surgery: RR interval, PR interval, QRS interval, QT interval and JT interval. Data are normally distributed (Shapiro-Wilk-test). * P<0.05 vs. WT-TAC, † P<0.05 vs. KI-TAC, using one-way ANOVA with Holm-Sidak post-test.

| Electrocardiographic parameters | WT       | WT Sham 6 weeks | WT TAC 6 weeks | KI       | KI Sham 6 weeks | KI TAC 6 weeks |
|---------------------------------|----------|-----------------|----------------|----------|----------------|----------------|
| Number of mice                  | 7        | 7               | 12             | 4        | 4              | 12             |
| RR Interval (s)                 | 0.13±0.004 | 0.13±0.006     | 0.13±0.005     | 0.12±0.008 | 0.13±0.009    | 0.14±0.007     |
| PR Interval (ms)                | 35.6±0.949 | 36.0±1.532     | 45.6±2.052     | 35.6±0.785 | 37.2±2.818    | 44.7±6.194     |
| P Duration (ms)                 | 9.73±2.27  | 7.65±0.55      | 9.47±0.61      | 9.42±1.62  | 13.9±3.41     | 8.83±0.61      |
| QRS Interval (ms)               | 8.35±0.52 * | 8.15±0.40 *    | 12.36±0.85     | 8.87±0.24 † | 8.17±0.92 †   | 12.25±1.35     |
| QT Interval (ms)                | 17.7±1.8 * | 19.0±2.6 *     | 34.1±2.5       | 18.8±0.8 † | 22.2±5.7 †    | 33.6±2.4       |
| QTc (ms)                        | 48.8±5.4 * | 52.7±7.5 *     | 94.5±7.0       | 54.3±1.2 † | 63.2±17.3 †   | 92.1±7.1       |
| JT Interval (ms)                | 9.3±1.8 *  | 10.4±2.5 *     | 21.7±1.9       | 9.9±0.7 †  | 14.0±5.3 †    | 21.3±1.5       |
| Tpeak Tend Interval (ms)        | 7.30±1.61 * | 8.53±2.40 *    | 14.05±1.32     | 7.96±0.67 † | 3.02±0.68 †   | 14.02±0.78     |
**Capillary density (capillaries/mm²)**

- **TW-ANOVA**
  - **p < 0.05 for interaction**
  - **WT**
    - BL: n=2/30
    - 1 w: n=3/45
    - 6 w: n=6/90
  - **KI**
    - BL: n=3/47
    - 1 w: n=3/50
    - 6 w: n=4/411

- **n=3/45**
- **n=2/30**
- **n=7/105**
- **n=4/389**

**Fibrosis (in %)**

- **TW-ANOVA**
  - **p = n.s. for interaction**
  - **WT**
    - BL: n=2
    - 1 w: n=3
    - 6 w: n=4
  - **KI**
    - BL: n=2
    - 1 w: n=6
    - 6 w: n=7

- **n=2**
- **n=6**
- **n=7**

**Cross sectional area (µm²)**

- **TW-ANOVA**
  - **p < 0.05 for interaction**
  - **WT**
    - BL: n=2/30
    - 1 w: n=3/45
    - 6 w: n=6/90
  - **KI**
    - BL: n=3/47
    - 1 w: n=3/50
    - 6 w: n=4/411

- **n=2/30**
- **n=3/45**
- **n=6/90**
- **n=4/389**

**Fig. S1**
Fig. S2

A

Mean blood pressure (in mmHg)

TW-ANOVA
p=n.s. for interaction

n=3

n=4

BL AngII

KI

WT

Heart rate (in bpm)

TW-ANOVA
p=n.s. for interaction

n=3

n=4

BL AngII
Fig. S3

A

Sham

B

TAC

C

RM TW-ANOVA
p=n.s. for interaction
Fig. S4

A

|       | WT  | KI  |
|-------|-----|-----|
| 205 kD|      |     |
| 205 kD|      |     |
| 37 kD |      |     |

B

**p-LTCC/LTCC**

|        | WT  | WT  | KI  | KI  |
|--------|-----|-----|-----|-----|
| TAC -  |     | 4   | 3   | 2   |
| TAC +  |     |     | 4   |     |

C

D

**PKARila dimer/monomer ratio (a.u.)**

|        | WT     | Nox4 KO |
|--------|--------|---------|
|         |        |         |
| 100 kD  |        |         |
| 50 kD   |        |         |

Dimer

Monomer

Downloaded from http://ahajournals.org by on February 11, 2022
Fig. S5

A

WT TAC  KI TAC

B

\( \text{QT}_{c} \text{ interval (s)} \)

|        | BL | Sham | TAC |
|--------|----|------|-----|
| WT     | 7  | 7    | 12  |
| KI     | 4  | 4    | 12  |

C

D

Number of mice

- Arrhythmia
- No Arrhythmia

|        | Sham | TAC |
|--------|------|-----|
| WT     | 5    | 5   |
| KI     | 5    | 5   |
Supplemental figure legends

Figure S1. KI hearts have aggravated structural remodeling late after TAC. Average data (A) and representative images (B) of cross-sectional myocyte’s area show a TAC-related increase in cell size that becomes significantly aggravated in KI late after TAC (i.e. at 6 weeks). Average data (C) and representative images (D) of a TAC-related increase in fibrosis in both genotypes. Mean values (E) and representative images (F) illustrate a TAC-related decrease in capillary density in both genotypes. Data are normally distributed (Shapiro-Wilk-test).*indicates significance vs. baseline, #indicates significance vs. WT, $indicates significance vs. previous phase using two-way ANOVA with Holm-Sidak post-test.

Figure S2. Long-term treatment with pressor doses of AngII induce a similar hypertensive response in WT and KI mice. Suppl. Fig. 2A demonstrates a similar increase in mean blood pressure following 14 days of AngII treatment at 1.0 mg·kg$^{-1}·d^{-1}$. Suppl. Fig. 2B illustrates comparable heart rates in WT and KI mice both at baseline and following long-term AngII treatment. Data are normally distributed (Shapiro-Wilk-test).*indicates significance vs. baseline, using two-way ANOVA with Holm-Sidak post-test.

Figure S3. Increased cAMP generation following TAC. Original images of isolated ventricular Epac1-camps mouse myocytes obtained by FLIM-FRET using a confocal microscope following sham (A) or TAC (B) surgery. Changes in decay time (ps) were used as a measure of cAMP concentration. Following measurement fluorescence lifetime at baseline (images 1-3), maximum stimulation of cAMP formation by Forskolin (50 μM) was induced (images 4-15). C: Average data for A and B. Data are normally distributed (Kolmogorov-Smirnov test). #indicates significance vs. WT using two-way RM ANOVA with Holm-Sidak post-test.

Figure S4. TAC is associated with increased LTCC serine-1928 phosphorylation in WT hearts only. Suppl. Fig. 4A&B depict original scans (A) and mean densitometric values (B) for Western blot analysis of Ca$\text{v}1.2$ expression and phosphorylation a serine-1928 (p-LTCC) in cardiac tissue from WT and KI mice following sham or TAC-surgery, respectively. Data are normally distributed (Shapiro-Wilk-test). *indicates significance vs WT+AngII using one-way ANOVA with Holm-Sidak post-test. C&D depict original scans (C) and mean values (D) of PKAR{\textit{α}} dimer to monomer ratio in cardiac
tissue from WT and Nox4KO mice that have underwent pressure overload by abdominal aortic banding. Data are normally distributed (Shapiro-Wilk-test). *indicates significance vs. WT using unpaired t-test.

Figure S5. Comparable electrical remodeling and ventricular arrhythmias in failing WT and KI mice

Figure depicts A original surface ECG traces (lead II) from WT and KI mice. B: Mean data for heart rate corrected QT interval according to Mitchell's formula. TAC resulted in a significantly increased QT interval. Data are normally distributed (Shapiro-Wilk-test). *indicates significance vs. baseline (BL), †indicates significance vs. WT-Sham, ‡indicates significance vs. KI-Sham (one-way ANOVA mixed effects model). C: Original surface ECG traces (lead II) during programmed electrical stimulation in vivo (burst) revealed ventricular tachycardia in both WT and KI mice. D: Mean data for the propensity of ventricular arrhythmias. No arrhythmias were induced in sham-treated animals. In contrast, a substantial amount of ventricular arrhythmias were induced in TAC-treated mice with no difference between WT and KI (Fisher's exact test).